Ocular, systemic and antinuclear antibody changes with acebutolol

JAMES HOSIE, MB, MRCP
General Practitioner, Glasgow

SALAHUDIN Y. A. GHAFOOR, MB, FRCS (Glas.)
Senior Registrar in Ophthalmology, Southern General Hospital, Glasgow

SUMMARY. A group of 29 hypertensive patients were studied for side effects of acebutolol. An antinuclear antibody titre of $\geq 1/64$ developed in 23 per cent of patients during a 12-month course of treatment. Full ophthalmic examination before and after the treatment period showed a statistically significant increase in tear secretion at one year. One patient had a slight worsening of her psoriasis. No patients developed any symptoms or signs of oculomucocutaneous syndrome (OMCS) or systemic lupus erythematosus (SLE).

Introduction

An association between the use of practolol and the development of oculomucocutaneous syndrome (OMCS) and systemic lupus erythematosus (SLE) has been suggested. So far as we know there is no definite link between any other beta blocker and OMCS, although an atypical example was reported with oxprenolol in a woman who developed psoriasis and keratoconjunctivitis sicca. Antinuclear antibody (ANA) was found in 30 per cent of 20 female patients on practolol, and up to 64 per cent of patients on practolol who developed subconjunctival fibrosis showed a positive rise in ANA. Subsequent work has thrown doubt on the relationship of drug-induced lupus syndrome and OMCS, although the former condition is now thought to have a benign course compared with the fatal outcome in OMCS. Monitoring patients for ANA is thus only useful for detecting drug-induced lupus. Wright found that 100 per cent of 27 patients developing OMCS had ANA. Wilson has named many cardiovascular drugs which produce a significant rise in ANA, including acebutolol, a cardioselective beta-adrenergic receptor blocking drug possessing both intrinsic sympathomimetic activity and membrane stabilizing activity. In a small series of patients taking acebutolol 88 per cent (eight out of nine patients) developed positive ANA on high dosage of the drug whereas in a larger series the incidence was 32 per cent (eight out of 25 patients). Moreover, there has been one possible case of systemic lupus erythematosus connected with a large dosage of acebutolol (1,600 mg).

We carried out a prospective study of the side effects of acebutolol on a group of hypertensive patients, measuring the serum titre of ANA and any ocular changes to investigate a possible correlation between the two.

Methods

Twenty-nine patients with mild hypertension—24 women and five men (average age 59.7 years, range 43.0–69.5 years)—were studied. These were the only new patients with mild hypertension who presented during the recruitment period in a practice with a female to male ratio of 2:1 in the over 50-year-olds.

All patients had a phase 5 sitting diastolic pressure measurement of at least 100 mmHg on three separate visits before treatment and were then treated in general practice for 12 months with acebutolol taken once daily.

Of the 29 patients, 24 had never received drug treatment for high blood pressure, five had received treatment for hypertension in the past but none in the previous 12 months. Twelve of the patients smoked cigarettes. Three patients were on concomitant long-term therapy: one patient was using cimetidine, one was using lactulose, and one was using intermittent prednisolone for rheumatoid arthritis. No other type of hypotensive drug was used during the study.

The following tests were carried out.

Ocular tests. Full ophthalmological examination included measurement of visual acuity for both near and distance sight, slit-lamp examination of precorneal and marginal tear film, biomicroscopic examination of conjunctiva for papillary changes, Schirmer's augmented test prior to Rose Bengal dye test, corneal staining with Rose Bengal and fluorescein dyes, visual screening using the Friedman field analyser.

Other tests. Measurements were made of the levels of haemoglobin, white cell count, platelets, urea, electrolytes, creatinine, alkaline phosphatase, transaminases, and bilirubin. An electrocardiogram (ECG) and a chest radiograph were also obtained.

Antinuclear antibody (ANA) test. The methods used to measure ANA and DNA binding have been described before. DNA binding was determined in all patients who developed an ANA titre of at least 1/64.

The laboratory tests were performed ‘blind’ by being included in the routine test requests sent to the hospital, and the laboratory observers were unaware of the clinical trial being.
conducted. Previous experience of dealing with this laboratory for other investigations has shown that reproducibility can be assured. The laboratory tests were performed before admission to the study and at one year.

After admission to the study, patients were seen at two weeks, four weeks and then every four weeks for a period of 12 months. During these visits, blood pressure was measured by the same observer in the same room, at the same time of day (where possible) and in the same arm (non-dominant), with the patient lying down for 10 minutes and then standing. The dose of acebutolol was titrated until diastolic pressure measurement was 95 mmHg or less in all patients.

Compliance

Out of a possible 15 visits, 21 of the patients attended 15 times, six attended 14 times, one attended 12 times and one attended only 10 times. Blood acebutolol concentrations were measured before treatment and from four to seven times during the 12 months of treatment in each patient. One patient who attended only 10 times had no detectable acebutolol level in plasma on all four occasions and was excluded from the analysis.

Statistical analysis

A paired Student's t test was applied to the results of the Schirmer's test and the intraocular pressure data. A non-parametric sign test was used for the results of the Rose Bengal and ANA tests. Product moment correlation coefficients were calculated for the correlation between the Schirmer's test and ANA test results.

Results

Eye changes

Tear secretion, as measured by Schirmer's test, was significantly increased following treatment with acebutolol (0.05>P>0.02) but there were no significant changes in intraocular pressure (0.5>P>0.1). In one patient (ANA negative) there was a marked fall in tear secretions in both eyes.

Conjunctival examination with Rose Bengal stain showed punctate staining in 12 eyes (seven patients) before treatment and in 19 eyes (10 patients) after treatment. Statistically these changes were not significant (P>0.5).

Corneal fluorescein dye test was negative in all patients, and there were no significant changes in vision during the period of study.

ANA changes

Initially 27 patients had negative or weakly positive values of ANA (22 negative and five weakly positive). Two patients had serum titres above 1/64 before entry to the study, but neither patient had been on hypotensive or cardiovascular drugs in the past.

Of the 26 patients who were initially negative or weakly positive and who complied with therapy, six (all females) had increases in serum titres to at least 1/64 at 12 months, in one case reaching 1/256 (Table 1). None of these six patients had a positive test for DNA antibody. The average age of those developing ANA was similar to that of the study as a whole.

| Table 1. Details of six patients who developed raised values of antinuclear antibody (ANA). |
|---|---|---|---|---|
| Age | Initial | Titre at | Titre at | Final dose of |
| Patient (years) | titre | 6 months | 12 months | acebutolol |
| 1 | 67 | Negative | WP | 1/64 | 500 |
| 2 | 66 | Negative | WP | 1/64 | 800 |
| 3 | 58 | Negative | WP | 1/64 | 800 |
| 4 | 52 | Negative | 1/64 | 1/256 | 1,000 |
| 5 | 52 | Negative | 1/64 | 1/64 | 400 |
| 6 | 61 | WP | WP | 1/64 | 400 |

WP = weakly positive.

Overall there was no significant correlation between the average Schirmer's results for the two eyes and the ANA results either before or after treatment (P>0.1). Nor was there any significant correlation between the change in the Schirmer's test result, averaged for the two eyes, and the change in ANA results (P>0.1).

End points and side effects

One patient developed polycythaemia rubra vera after 10 months; she became and remained normotensive after venesection and treatment with radioactive phosphorus. Although she stopped therapy on becoming normotensive, we observed her for the duration of the study and she had the same final investigations as the other patients. One patient developed an inferior myocardial infarction at eight months; after hospital discharge she became hypertensive again, although she was then maintained on a lower dose of acebutolol.

In response to a monthly questionnaire of 39 items answered in the surgery, one patient complained of wheeze, two of cold extremeties, two of calf cramps, one of indigestion, one of dry mouth, one of excessive dreaming, and one of a slight worsening of her psoriasis which improved after the drug was stopped.

In response to two questions about ocular problems, which were 'Have you had any other eye symptoms or signs?' and 'Have you had conjunctivitis?', there were no affirmative answers. There were no significant changes in blood indices, biochemistry or urine. There were no ECG changes in any of the patients apart from the woman who had an inferior myocardial infarction. Specifically there were no clinical signs in any of the patients that were suggestive of SLE or OMCS.

Discussion

We found that, with acebutolol, there was an increased incidence of antinuclear antibody (ANA) in patients on no other hypotensive therapy and we also found that a titre of ANA increased with time, confirming the work of Cody and colleagues.\textsuperscript{12}

All patients who developed a positive titre of antinuclear antibody were taking 400 mg or more of acebutolol per day. None of the seven patients on less than
ASSOCIATESHIP of the Royal College of General Practitioners

Any doctor who is registered or provisionally registered with the General Medical Council may become an Associate of the College without having to pass an examination. Associates may take part in all College activities but are not able to describe themselves as MRCGP or to vote at general meetings. Together with Members and Fellows they undertake to uphold and promote the aims of the College to the best of their ability and, while in active practice, to continue as far as practicable approved postgraduate study.

The benefits of Associateship include:

1. A sense of belonging to an organization dedicated to improving the standards of care in general practice.
2. Membership of a local faculty of the College, and participation in its activities including education and research.
3. Access to the services of the College library. This is probably the most extensive library of general practice in the world and is staffed by librarians used to handling enquiries from general practitioners. New reading for general practitioners is produced quarterly for those who wish to keep up to date with the growing literature of general practice.
4. The Journal (the oldest journal of original general practice research), its associated publications and monographs.
5. Eligibility to compete for certain awards, prizes and fellowships available only to College Fellows, Members and Associates.
6. The use of College Headquarters at 14 Princess Gate, and in particular of the comfortable bed and breakfast accommodation it provides in central London at very reasonable rates.

Details of the entrance fee and current annual subscription are available on request by completing the form below. Reduced rates are available to several categories of doctor, particularly those undergoing vocational training for general practice.

To the Membership Secretary
The Royal College of General Practitioners
14 Princes Gate, Hyde Park
London SW7 1PU. Tel: 01-581 3232

Please send me an application form to become an Associate

Name ..........................................................................................
Address ....................................................................................
..............................................................................................
..............................................................................................

J. Hosie and S. Y. A. Ghafoor

400 mg per day developed a positive titre. This partially confirms the previously reported results, where positive titres occurred only in those patients on a daily dosage greater than 400 mg acebutolol. We found an increase in tear secretion (measured by Schirmer’s test) similar to that noted by Shapiro and colleagues; they suggested that the increase is an irritability mediated reflex leading later perhaps to exhaustion, but there is no evidence to prove this. There were no other significant ocular changes.

We could not demonstrate any correlation between the development of positive titres of ANA and ocular or skin changes. However, the high incidence of positive ANA in patients while taking acebutolol implies that careful observation of such patients for ocular or cutaneous problems should be carried out in the longer term, particularly if the daily dose of the drug is greater than 400 mg.

We would suggest that the ANA measurement could be used in patients on 400 mg or more of acebutolol at one year as a warning guide similar to that suggested recently for hydralazine for detection of drug-induced lupus.

References


Acknowledgements

We thank Dr J. Williamson and Dr Peter Semple for helpful criticism, Dr D. Allan for statistical analysis, and Mrs Ann Fergus for typing and secretarial help. We also thank May & Baker Ltd for financial support and tablet supply.

Address for correspondence
Dr J. Hosie, The Surgery, 1980 Great Western Road, Glasgow G13 2SW.

782 Journal of the Royal College of General Practitioners, December 1983